The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.
 
Rajwanth Veluswamy
Consulting or Advisory Role - AstraZeneca; BeiGene; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Merus; Novocure; Regeneron
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Onconova Therapeutics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Sheena Bhalla
Consulting or Advisory Role - Mirati Therapeutics; Takeda
 
Ranee Mehra
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Consulting or Advisory Role - Coherus Biosciences; Janssen Oncology
Research Funding - AstraZeneca; Merck
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Blueprint Pharmaceutic; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; MSD Oncology; Novartis; Pfizer; Regeneron; Roche; Sanofi/Aventis; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; GlaxoSmithKline; Incyte; Inivata; Janssen; Lilly; MSD; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Oleg Gligich
No Relationships to Disclose
 
Cristina Oliva
Employment - BerGenBio
Stock and Other Ownership Interests - BerGenBio
 
Claudia Gorcea-Carson
Employment - BerGenBio
Stock and Other Ownership Interests - BerGenBio
 
Nigel William McCracken
Employment - BerGenBio
Stock and Other Ownership Interests - BerGenBio